Back to today’s briefing

Story perspectives

AmplifyBio Closes After Failed Investment Efforts

4/7/2025

42 8

Summary

Story summary

AmplifyBio, a promising Ohio-based company specializing in cell and gene therapies, has tragically closed its doors after failing to attract necessary investments in a tough market. Launched in 2021 with a hefty $200 million, the firm faced painful layoffs and operational cuts, ultimately succumbing to the harsh realities of the industry despite its early ambitions.

1 of 1

Story summary

AmplifyBio, a promising Ohio-based company specializing in cell and gene therapies, has tragically closed its doors after failing to attract necessary investments in a tough market. Launched in 2021 with a hefty $200 million, the firm faced painful layoffs and operational cuts, ultimately succumbing to the harsh realities of the industry despite its early ambitions.